Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Active, not recruiting · NCT03304080 · Registry updated 2026-07-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT03304080 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Herbert Irving Comprehensive Cancer Center | 4 |
| Icahn School of Medicine at Mount Sinai | 256 |
| NYU Langone Health | 359 |
| Weill Medical College of Cornell University | 276 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mount Sinai Beth Israel Comprehensive Cancer Center West | New York | United States | 1 |
| Mount Sinai West | New York | United States | 78 |
| New York Presbyterian Columbia Irving Comprehensive Cancer Center | New York | United States | 1 |
| New York Presbyterian Weill Cornell Medical Center | New York | United States | 2 |
| Perlmutter Cancer Center NYU Langone | New York | United States | 1 |